{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T09:53:00Z","timestamp":1791193980631,"version":"4.1.0"},"reference-count":63,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological Psychiatry"],"published-print":{"date-parts":[[2007,1]]},"DOI":"10.1016\/j.biopsych.2006.04.043","type":"journal-article","created":{"date-parts":[[2006,9,2]],"date-time":"2006-09-02T07:22:12Z","timestamp":1157181732000},"page":"101-110","source":"Crossref","is-referenced-by-count":115,"title":["Buprenorphine Duration of Action: Mu-opioid Receptor Availability and Pharmacokinetic and Behavioral Indices"],"prefix":"10.1016","volume":"61","author":[{"given":"Mark","family":"Greenwald","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris-Ellyn","family":"Johanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Bueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Moody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kilbourn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Koeppe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon-Kar","family":"Zubieta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopsych.2006.04.043_bib1","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/0024-3205(94)00848-5","article-title":"Alternate-day dosing during buprenorphine treatment of opioid dependence","volume":"54","author":"Amass","year":"1994","journal-title":"Life Sci"},{"key":"10.1016\/j.biopsych.2006.04.043_bib2","first-page":"173","article-title":"Differential down- and up-regulation of rat brain opioid receptor types and subtypes by buprenorphine","volume":"44","author":"Belcheva","year":"1993","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.biopsych.2006.04.043_bib3","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.biopsych.2003.07.007","article-title":"Mu-opioid receptor binding measured by [11C]carfentanil positron emission tomography is related to craving and mood in alcohol dependence","volume":"55","author":"Bencherif","year":"2004","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2006.04.043_bib4","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s002130051096","article-title":"Buprenorphine dosing every 1, 2, or 3 days in opioid-dependent patients","volume":"146","author":"Bickel","year":"1999","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.biopsych.2006.04.043_bib5","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/0014-5793(88)81294-8","article-title":"Differential regulation of mu-opiate receptors in heroin- and morphine-dependent rats","volume":"234","author":"Bolger","year":"1988","journal-title":"FEBS Lett"},{"key":"10.1016\/j.biopsych.2006.04.043_bib6","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1016\/0024-3205(91)90150-A","article-title":"Mu receptor binding of some commonly used opioids and their metabolites","volume":"48","author":"Chen","year":"1991","journal-title":"Life Sci"},{"key":"10.1016\/j.biopsych.2006.04.043_bib7","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/0020-708X(85)90089-4","article-title":"Radiosynthesis of an opiate receptor binding radiotracer: [11C]-carfentanil","volume":"36","author":"Dannals","year":"1985","journal-title":"Int J Appl Radiat Isot"},{"key":"10.1016\/j.biopsych.2006.04.043_bib8","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/0304-3940(90)90491-Q","article-title":"Nicotine protects against mu-opioid receptor antagonism by beta-funaltrexamine: Evidence for nicotine-induced release of endogenous opioids in brain","volume":"113","author":"Davenport","year":"1990","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.biopsych.2006.04.043_bib9","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0376-8716(97)01347-1","article-title":"Controlled opioid withdrawal evaluation during 72-h dose omission in buprenorphine-maintained patients","volume":"45","author":"Eissenberg","year":"1997","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.biopsych.2006.04.043_bib10","series-title":"Structured Clinical Interview for DSM-IV Axis Disorders\u2013Patient Edition (SCID-I\/P, version 2.0)","author":"First","year":"1996"},{"key":"10.1016\/j.biopsych.2006.04.043_bib11","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/clpt.1990.67","article-title":"Use of buprenorphine in the treatment of opioid addiction","volume":"47","author":"Fudala","year":"1990","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.biopsych.2006.04.043_bib12","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.biopsych.2005.02.026","article-title":"Imaging brain mu-opioid receptors in abstinent cocaine users: Time course and relation to cocaine craving","volume":"57","author":"Gorelick","year":"2005","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2006.04.043_bib13","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1037\/1064-1297.10.1.39","article-title":"Heroin craving and drug use in opioid-maintained volunteers: Effects of methadone dose variations","volume":"10","author":"Greenwald","year":"2002","journal-title":"Exp Clin Psychopharmacol"},{"key":"10.1016\/j.biopsych.2006.04.043_bib14","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.pbb.2003.10.003","article-title":"Effects of opioid dependence and tobacco use on ventilatory response to progressive hypercapnia","volume":"77","author":"Greenwald","year":"2004","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.biopsych.2006.04.043_bib15","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1037\/1064-1297.13.1.3","article-title":"Opioid craving and seeking behavior in physically dependent volunteers: Effects of acute withdrawal and drug reinforcement opportunity","volume":"13","author":"Greenwald","year":"2005","journal-title":"Exp Clin Psychopharmacol"},{"key":"10.1016\/j.biopsych.2006.04.043_bib16","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1037\/1064-1297.14.1.52","article-title":"Early impact of methadone induction for heroin dependence: Differential effects of two dose sequences in a randomized controlled study","volume":"14","author":"Greenwald","year":"2006","journal-title":"Exp Clin Psychopharmacol"},{"key":"10.1016\/j.biopsych.2006.04.043_bib17","unstructured":"Greenwald MK. Human experimental therapeutic models in opioid dependence: Translational research advances and implications. In: Columbus F, ed. Heroin Addiction: New Research. New York: Nova Science, in press."},{"key":"10.1016\/j.biopsych.2006.04.043_bib18","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1038\/sj.npp.1300251","article-title":"Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers","volume":"28","author":"Greenwald","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2006.04.043_bib19","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0376-8716(99)00032-0","article-title":"Opioid reinforcement in heroin-dependent volunteers during buprenorphine maintenance","volume":"56","author":"Greenwald","year":"1999","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.biopsych.2006.04.043_bib20","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1007\/s00213-001-0975-0","article-title":"Effects of buprenorphine sublingual tablet maintenance on opioid drug-seeking behavior by humans","volume":"160","author":"Greenwald","year":"2002","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.biopsych.2006.04.043_bib21","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0376-8716(00)00227-1","article-title":"Limits to buprenorphine dosing: A comparison between quintuple and sextuple the maintenance dose every 5 days","volume":"64","author":"Gross","year":"2001","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.biopsych.2006.04.043_bib22","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0014-2999(99)00904-8","article-title":"Opioid activity profiles indicate similarities between the nociceptin\/orphanin FQ and opioid receptors","volume":"389","author":"Hawkinson","year":"2000","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.biopsych.2006.04.043_bib23","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1001\/archpsyc.62.1.57","article-title":"Correlation of stable elevations in striatal mu-opioid receptor availability in detoxified alcoholic patients with alcohol craving: A positron emission tomography study using carbon 11-labeled carfentanil","volume":"62","author":"Heinz","year":"2005","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2006.04.043_bib24","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/S0022-3565(24)29586-0","article-title":"Comparison of pharmacological activities of buprenorphine and nor-buprenorphine: Nor-buprenorphine is a potent opioid agonist","volume":"297","author":"Huang","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.biopsych.2006.04.043_bib25","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/cpt196892215","article-title":"Antagonism of the subjective, behavioral, pupillary, and respiratory depressant effects of cyclazocine by naloxone","volume":"9","author":"Jasinski","year":"1968","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.biopsych.2006.04.043_bib26","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1001\/archpsyc.1978.01770280111012","article-title":"Human pharmacology and abuse potential of the analgesic buprenorphine","volume":"35","author":"Jasinski","year":"1978","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2006.04.043_bib27","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0969-8051(01)00226-8","article-title":"A simple synthesis of [11C]-carfentanil","volume":"28","author":"Jewett","year":"2001","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.biopsych.2006.04.043_bib28","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0376-8716(95)01189-7","article-title":"Buprenorphine treatment of opioid dependence: Clinical trial of daily versus alternate-day dosing","volume":"40","author":"Johnson","year":"1995","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.biopsych.2006.04.043_bib29","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1016\/S0376-8716(03)00060-7","article-title":"Buprenorphine: How to use it right","volume":"70","author":"Johnson","year":"2003","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.biopsych.2006.04.043_bib30","first-page":"1070","article-title":"Opioid receptor imaging with positron emission tomography and [(18)F]cyclofoxy in long-term, methadone-treated former heroin addicts","volume":"295","author":"Kling","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.biopsych.2006.04.043_bib31","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1046\/j.1360-0443.1998.93454910.x","article-title":"Relationship of plasma buprenorphine and norbuprenorphine to withdrawal symptoms during dose induction, maintenance, and withdrawal from sublingual buprenorphine","volume":"93","author":"Kuhlman","year":"1998","journal-title":"Addiction"},{"key":"10.1016\/j.biopsych.2006.04.043_bib32","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0014-2999(99)00460-4","article-title":"Differential binding properties of oripavines at cloned mu- and delta-opioid receptors","volume":"378","author":"Lee","year":"1999","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.biopsych.2006.04.043_bib33","doi-asserted-by":"crossref","first-page":"717","DOI":"10.2174\/1381612043453027","article-title":"The orvinols and related opioids\u2013high affinity ligands with diverse efficacy profiles","volume":"10","author":"Lewis","year":"2004","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.biopsych.2006.04.043_bib34","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1097\/00004647-199609000-00008","article-title":"Distribution volume ratios without blood sampling from graphical analysis of PET data","volume":"16","author":"Logan","year":"1996","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1016\/j.biopsych.2006.04.043_bib35","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0022-3956(69)90007-7","article-title":"Physiological parameters of morphine dependence in man\u2014tolerance, early abstinence, protracted abstinence","volume":"7","author":"Martin","year":"1969","journal-title":"J Psychiatr Rev"},{"key":"10.1016\/j.biopsych.2006.04.043_bib36","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S1361-8415(97)85010-4","article-title":"Demonstration of accuracy and clinical versatility of mutual information for automatic multimodality image fusion using affine and thin-plate spline warped geometric deformations","volume":"1","author":"Meyer","year":"1997","journal-title":"Med Image Anal"},{"key":"10.1016\/j.biopsych.2006.04.043_bib37","first-page":"1579","article-title":"An automated method for rotational correction and centering of three-dimensional functional brain images","volume":"33","author":"Minoshima","year":"1992","journal-title":"J Nucl Med"},{"key":"10.1016\/j.biopsych.2006.04.043_bib38","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1006\/abio.2002.5673","article-title":"A liquid chromatographic-electrospray ionization-tandem mass spectrometric method for determination of buprenorphine, its metabolite, norbuprenorphine, and a coformulant, naloxone, that is suitable for in vivo and in vitro metabolism studies","volume":"306","author":"Moody","year":"2002","journal-title":"Anal Biochem"},{"key":"10.1016\/j.biopsych.2006.04.043_bib39","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/00008877-200211000-00005","article-title":"Delta opioid antagonist effects of buprenorphine in rhesus monkeys","volume":"13","author":"Negus","year":"2002","journal-title":"Behav Pharmacol"},{"key":"10.1016\/j.biopsych.2006.04.043_bib40","first-page":"348","article-title":"Ventilation in morphine-maintained rhesus monkeys","volume":"282","author":"Paronis","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.biopsych.2006.04.043_bib41","first-page":"355","article-title":"Ventilation in morphine-maintained rhesus monkeys","volume":"282","author":"Paronis","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.biopsych.2006.04.043_bib42","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S0009-9236(99)70039-1","article-title":"A comparison of four buprenorphine dosing regimens in the treatment of opioid dependence","volume":"66","author":"Petry","year":"1999","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.biopsych.2006.04.043_bib43","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1046\/j.1360-0443.2001.9668234.x","article-title":"Examining the limits of the buprenorphine interdosing interval: Daily, every-third-day and every-fifth-day dosing regimens","volume":"96","author":"Petry","year":"2001","journal-title":"Addiction"},{"key":"10.1016\/j.biopsych.2006.04.043_bib44","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/imj.1967.16.1.20","article-title":"A clinical method for assessing the ventilatory response to carbon dioxide","volume":"16","author":"Read","year":"1967","journal-title":"Austral Ann Med"},{"key":"10.1016\/j.biopsych.2006.04.043_bib45","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1378\/chest.70.1_Supplement.118","article-title":"Measurement of ventilatory response to CO2 by rebreathing","volume":"70","author":"Rebuck","year":"1976","journal-title":"Chest"},{"key":"10.1016\/j.biopsych.2006.04.043_bib46","series-title":"The Pharmacological Basis of Therapeutics, 9th ed.","first-page":"521","article-title":"Opioid analgesics and antagonists","author":"Reisine","year":"1996"},{"key":"10.1016\/j.biopsych.2006.04.043_bib47","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0014-2999(85)90379-6","article-title":"In vivo opiate receptor binding of oripavines to mu, delta and kappa sites in rat brain as determined by an ex vivo labeling method","volume":"114","author":"Richards","year":"1985","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.biopsych.2006.04.043_bib48","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/0376-8716(94)90121-X","article-title":"Buprenorphine: Duration of blockade of effects of intramuscular hydromorphone","volume":"35","author":"Rosen","year":"1994","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.biopsych.2006.04.043_bib49","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/s002130051045","article-title":"Onset, magnitude and duration of opioid blockade produced by buprenorphine and naltrexone in humans","volume":"145","author":"Schuh","year":"1999","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.biopsych.2006.04.043_bib50","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1037\/1064-1297.3.4.424","article-title":"Measurement of drug craving during naloxone-precipitated withdrawal in methadone maintained volunteers","volume":"3","author":"Schuster","year":"1995","journal-title":"Exp Clin Psychopharmacol"},{"key":"10.1016\/j.biopsych.2006.04.043_bib51","doi-asserted-by":"crossref","unstructured":"Scott DJ, Domino EF, Heitzeg MM, Koeppe RA, Ni L, Guthrie S, Zubieta JK (in press): Smoking modulation of \u03bc-opioid and dopamine D2 receptor mediated neurotransmission in humans. Neuropsychopharmacology","DOI":"10.1038\/sj.npp.1301238"},{"key":"10.1016\/j.biopsych.2006.04.043_bib52","first-page":"809","article-title":"Decrease in delta and mu opioid receptor binding capacity in rat brain after chronic etorphine treatment","volume":"240","author":"Tao","year":"1987","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.biopsych.2006.04.043_bib53","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0165-3806(88)90176-9","article-title":"Morphine-induced downregulation of mu-opioid receptors in neonatal rat brain","volume":"469","author":"Tempel","year":"1988","journal-title":"Brain Res"},{"key":"10.1016\/j.biopsych.2006.04.043_bib55","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/0014-2999(89)90582-7","article-title":"Mu opiate receptors are selectively labelled by [3H]-carfentanil in human and rat brain","volume":"167","author":"Titeler","year":"1989","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.biopsych.2006.04.043_bib56","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1007\/BF00169310","article-title":"Modulation of brain alpha 2-adrenoceptor and mu-opioid receptor densities during morphine dependence and spontaneous withdrawal in rats","volume":"336","author":"Ulibarri","year":"1987","journal-title":"Naunyn Schmiedebergs Arch Pharmakol"},{"key":"10.1016\/j.biopsych.2006.04.043_bib57","doi-asserted-by":"crossref","first-page":"10388","DOI":"10.1073\/pnas.93.19.10388","article-title":"Relationship between psychostimulant-induced \u201chigh\u201d and dopamine transporter occupancy","volume":"93","author":"Volkow","year":"1996","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.biopsych.2006.04.043_bib58","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0006-8993(99)01095-1","article-title":"The effect of chronic administration of nicotine on antinociception, opioid receptor binding and met-enkephalin levels in rats","volume":"822","author":"Wewers","year":"1999","journal-title":"Brain Res"},{"key":"10.1016\/j.biopsych.2006.04.043_bib59","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1124\/mol.56.2.334","article-title":"Agonist effect of buprenorphine in a nociceptin\/OFQ receptor-triggered report gene assay","volume":"56","author":"Wnendt","year":"1999","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.biopsych.2006.04.043_bib60","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1124\/jpet.105.100859","article-title":"Buprenorphine activates \u03bc and opioid receptor like-1 receptors simultaneously, but the analgesic effect is mainly mediated by \u03bc receptor activation in rat formalin test","volume":"318","author":"Yamamoto","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.biopsych.2006.04.043_bib61","series-title":"Shipley Institute of Living Scale: Revised Manual","author":"Zachary","year":"1991"},{"key":"10.1016\/j.biopsych.2006.04.043_bib62","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S0022-3565(24)35398-4","article-title":"Ligand-induced changes in surface \u03bc-opioid receptor number: Relationship to G protein activation","volume":"292","author":"Zaki","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.biopsych.2006.04.043_bib63","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1038\/nm1196-1225","article-title":"Increased mu opioid receptor binding detected by PET in cocaine-dependent men is associated with cocaine craving","volume":"2","author":"Zubieta","year":"1996","journal-title":"Nat Med"},{"key":"10.1016\/j.biopsych.2006.04.043_bib64","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/S0893-133X(00)00110-X","article-title":"Buprenorphine-induced changes in mu-opioid receptor availability in male heroin-dependent volunteers: A preliminary study","volume":"23","author":"Zubieta","year":"2000","journal-title":"Neuropsychopharmacology"}],"container-title":["Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322306005890?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322306005890?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T14:02:12Z","timestamp":1736517732000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006322306005890"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1]]},"references-count":63,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,1]]}},"alternative-id":["S0006322306005890"],"URL":"https:\/\/doi.org\/10.1016\/j.biopsych.2006.04.043","relation":{},"ISSN":["0006-3223"],"issn-type":[{"value":"0006-3223","type":"print"}],"subject":[],"published":{"date-parts":[[2007,1]]}}}